528 filings
Page 3 of 27
DEFA14A
5roid
8 Dec 23
Additional proxy soliciting materials
4:05pm
8-K
nq809x
8 Dec 23
Amendments to Articles of Incorporation or Bylaws
4:05pm
8-K
o8nd56bp
15 Nov 23
Bio-path Holdings Reports Third Quarter 2023 Financial Results
7:30am
DEFA14A
meaku3ezf255hway xl
27 Oct 23
Additional proxy soliciting materials
4:35pm
8-K
x58g9mk
24 Oct 23
Regulation FD Disclosure
4:30pm
8-K
nam8 n333
15 Sep 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:30pm
8-K
sbq26upa2td7bbguxa
15 Aug 23
Bio-path Holdings Reports Second Quarter 2023 Financial Results
7:10am
8-K
axkbghqjccytjv
7 Aug 23
Bio-Path Holdings, Inc. Announces Pricing of $2.1 Million Public Offering
4:42pm
424B3
raliq2x5roi65s9p929j
7 Aug 23
Prospectus supplement
7:21am
424B4
d1uqz3u3l8qwwyubmve
7 Aug 23
Prospectus supplement with pricing info
7:16am
EFFECT
tybz8h
3 Aug 23
Notice of effectiveness
12:15am
8-K
vhzyp
1 Aug 23
Bio-Path Holdings Announces Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia
5:02pm
CORRESP
nlccm8b7
1 Aug 23
Correspondence with SEC
12:00am
CORRESP
co9qbfv5
1 Aug 23
Correspondence with SEC
12:00am
8-K
b3pldg
17 Jul 23
Bio-Path Holdings Announces Successful Completion of First Dose Cohort in Phase 1/1b Clinical Trial of BP1001-A in Solid Tumors
4:30pm